Biodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual MeetingBusiness Wire • 10/03/23
Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung CancerBusiness Wire • 09/07/23
Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing CancerBusiness Wire • 08/22/23
Biodesix to Participate in the Canaccord Genuity 43rd Annual Growth ConferenceBusiness Wire • 08/01/23
Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung NodulesBusiness Wire • 07/12/23
Biodesix Awarded Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid ServicesBusiness Wire • 07/06/23
Biodesix Completes Enrollment of INSIGHT Study Assessing Clinical Utility of the VeriStrat® Blood-Based Host Immune ClassifierBusiness Wire • 06/27/23
Biodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual MeetingBusiness Wire • 06/01/23
Biodesix to Participate in William Blair's 43rd Annual Growth Stock ConferenceBusiness Wire • 05/31/23
Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® TestingBusiness Wire • 05/25/23
Biodesix, Inc. Chief Financial Officer Robin Harper Cowie Appointed to Colorado BioScience Association's Board of DirectorsBusiness Wire • 05/24/23
Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to Be Presented at ATS 2023 International ConferenceBusiness Wire • 05/18/23
Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and HighlightsBusiness Wire • 03/06/23